

Mitchell S Von Itzstein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7434573/mitchell-s-von-itzstein-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

89
citations

5
h-index

9
g-index

24
ext. papers

190
ext. citations

5
avg, IF

3.04
L-index

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 20 | Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020 , 66, 779-793 | 5.5 | 32 |
| 19 | Strategies to maximize influenza vaccine impact in older adults. <i>Vaccine</i> , 2018 , 36, 5940-5948 | 4.1 | 11 |
| 18 | Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. <i>Oncologist</i> , 2020 , 25, e753-e757 | 5.7 | 8 |
| 17 | Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer. <i>Cancer</i> , 2019 , 125, 4252-4259 | 6.4 | 6 |
| 16 | Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , 2020 , 25, e1242-e1245 | 5.7 | 5 |
| 15 | Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base osteomyelitis. <i>BMJ Case Reports</i> , 2017 , 2017, | 0.9 | 5 |
| 14 | Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. <i>Lung</i> , 2019 , 197, 593-599 | 2.9 | 5 |
| 13 | Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. <i>Cancer Medicine</i> , 2020 , 9, 4137-4147 | 4.8 | 3 |
| 12 | Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. <i>Cancer</i> , 2020 , 126, 1605-1613 | 6.4 | 3 |
| 11 | Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020 , 15, 579-588 | 5 | 3 |
| 10 | Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , 2020 , 15, e0231258 | 3.7 | 2 |
| 9 | Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1 | 7.4 | 2 |
| 8 | Association between immune-related adverse event timing and treatment outcomes.. <i>OncImmunity</i> , 2022 , 11, 2017162 | 7.2 | 2 |
| 7 | Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors 2021 , 9, | | 1 |
| 6 | Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100291 | 1.4 | 0 |
| 5 | Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15126-e15126 | 2.2 | |
| 4 | Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3043-3043 | 2.2 | |

- 3 Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. *EBioMedicine*, **2020**, 60, 103006 8.8
- 2 Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. *JCO Oncology Practice*, **2021**, 17, e999-e1011 2.3
- 1 Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. *Cancer Research*, **2021**, 81, 3441-3443 10.1